Article Text

PDF

1471 Protocol Bfm-95 in Treatmant of Chilhood Acute Lymphoblastic Leukemia (All) and Lymphoblastic Lymphoma (Ll)
  1. E Bojadjieva1,2,
  2. K Martinova3
  1. 1Department of Pediarics, University Goce Delchev, Stip
  2. 2Department of Oncology and Haematology, University Children Hospital
  3. 3University Children Hospital, Skopje, FYR Macedonia

Abstract

Introduction ALL and LL as the most common malignant diseases in childhood are two related malignancies that are treated by the same protocols.

Aim The aim of the study is to see the outcome of the application of protocol BFM-95 in the treatment of ALL and LL in childhood in Macedonia in the period 2000–2007.

Method We analyzed the medical records of 88 pediatric patients treated at Department of Hematology and Oncology at the University Pediatric Clinic in Skopje, 69 of which with ALL and 19 with LL.

Results The annual average registered patients with ALL was 8.6 and 2.4 patients with LL. At the end of the study 85.5% patients with ALL and 42.1% patients with LL were alive. Regarding the outcome of the examined patients there were statistically significant differences between the two groups (p=0,0075). There is a strong correlation between the type of disease and the outcome of the disease in patients (p=0,00001). Relaps was registered in 7.3% patients with ALL and in 31.6% patients with LL, where the analysis showed that between the two studied groups there is statistically significant difference (p=0,0079). There is a correlation between the type of disease and the occurrence of relapse (p =0,0149). According to Kaplan-Meier-survival curve, a 5-year overall survival is 92.3% in the group with ALL and 43% in group with LL.

Conclusion Although these two related cancers are treated with the same protocols, with current therapeutic approaches the outcome is better for patients with ALL compared to patients with LL.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.